Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
(NASDAQ:AUTL), LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its third quarter 2025 financial results and operational highlights before open of U.S. markets on Wednesday, November 12, […]